Market Closed -
Toronto S.E.
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
9.19
CAD
|
+0.33%
|
|
+3.61%
|
+41.38%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,067
|
1,473
|
2,314
|
1,070
|
321.6
|
501.2
|
-
|
-
|
Enterprise Value (EV)
1 |
12,396
|
1,842
|
2,292
|
858.3
|
248.3
|
501.2
|
501.2
|
501.2
|
P/E ratio
|
-41.7
x
|
-0.45
x
|
-2.85
x
|
-0.62
x
|
-1.52
x
|
-5.87
x
|
-56.6
x
|
81.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
48.7
x
|
5.28
x
|
9.43
x
|
4.83
x
|
1.84
x
|
1.84
x
|
1.57
x
|
1.36
x
|
EV / Revenue
|
48.7
x
|
5.28
x
|
9.43
x
|
4.83
x
|
1.84
x
|
1.84
x
|
1.57
x
|
1.36
x
|
EV / EBITDA
|
-77.4
x
|
-7.17
x
|
-20.3
x
|
-21
x
|
-57.2
x
|
32
x
|
16.6
x
|
10.3
x
|
EV / FCF
|
-19.9
x
|
-2.13
x
|
-8.78
x
|
-7.53
x
|
-2.52
x
|
-7.28
x
|
-33.9
x
|
16.2
x
|
FCF Yield
|
-5.03%
|
-47%
|
-11.4%
|
-13.3%
|
-39.7%
|
-13.7%
|
-2.95%
|
6.18%
|
Price to Book
|
2.8
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,317
|
9,741
|
19,798
|
21,477
|
34,213
|
54,539
|
-
|
-
|
Reference price
2 |
1,451
|
151.2
|
116.9
|
49.80
|
9.400
|
9.190
|
9.190
|
9.190
|
Announcement Date
|
9/11/19
|
9/22/20
|
9/27/21
|
9/20/22
|
6/14/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
247.9
|
278.9
|
245.5
|
221.3
|
175
|
272
|
319.6
|
367.3
|
EBITDA
1 |
-156
|
-205.3
|
-114.1
|
-51.05
|
-5.625
|
15.68
|
30.14
|
48.62
|
EBIT
1 |
-338.6
|
-491
|
-282.8
|
-231.4
|
-158.1
|
-46.76
|
-11.68
|
15.62
|
Operating Margin
|
-136.58%
|
-176.03%
|
-115.21%
|
-104.57%
|
-90.36%
|
-17.19%
|
-3.65%
|
4.25%
|
Earnings before Tax (EBT)
1 |
-328.2
|
-3,384
|
-699.8
|
-1,720
|
-221.5
|
-75.98
|
-1.392
|
22.9
|
Net income
1 |
-290.8
|
-3,310
|
-695.1
|
-1,718
|
-199
|
-61.91
|
-7.752
|
5.591
|
Net margin
|
-117.3%
|
-1,186.9%
|
-283.17%
|
-776%
|
-113.73%
|
-22.76%
|
-2.43%
|
1.52%
|
EPS
2 |
-34.80
|
-339.4
|
-41.00
|
-79.90
|
-6.200
|
-1.566
|
-0.1625
|
0.1133
|
Free Cash Flow
1 |
-606.5
|
-693
|
-263.7
|
-142.1
|
-127.8
|
-68.87
|
-14.8
|
31
|
FCF margin
|
-244.61%
|
-248.46%
|
-107.41%
|
-64.18%
|
-73.03%
|
-25.32%
|
-4.63%
|
8.44%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
63.75%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
554.5%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/11/19
|
9/22/20
|
9/27/21
|
9/20/22
|
6/14/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
60.59
|
50.43
|
50.22
|
49.26
|
61.68
|
61.68
|
64.03
|
75.11
|
63.42
|
64.42
|
69.54
|
85.91
|
74.52
|
76.61
|
82.89
|
EBITDA
1 |
-9.04
|
-12.26
|
-12.85
|
-8.7
|
1.428
|
1.428
|
0.31
|
2.155
|
3.398
|
4.349
|
5.764
|
7.67
|
6.804
|
7.067
|
10.27
|
EBIT
1 |
-55.79
|
-72.38
|
-63.9
|
-53.82
|
-71.6
|
-71.6
|
-32.68
|
-16.11
|
-11.05
|
-23.89
|
-1.2
|
-
|
-
|
-
|
-
|
Operating Margin
|
-92.09%
|
-143.52%
|
-127.25%
|
-109.26%
|
-116.08%
|
-116.08%
|
-51.05%
|
-21.45%
|
-17.42%
|
-37.09%
|
-1.73%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-75.51
|
-1,012
|
-620.1
|
-63.86
|
-67.28
|
-67.28
|
-90.39
|
-22.11
|
0.384
|
-25.28
|
-3.629
|
-
|
-
|
-
|
-
|
Net income
1 |
-74.78
|
-1,012
|
-618.8
|
-51.6
|
-65.39
|
-67.2
|
-82
|
-26.9
|
-0.523
|
-25.56
|
-3.179
|
-
|
-
|
-
|
-
|
Net margin
|
-123.42%
|
-2,006.93%
|
-1,232.28%
|
-104.75%
|
-106.02%
|
-108.95%
|
-128.07%
|
-35.81%
|
-0.82%
|
-39.68%
|
-4.57%
|
-
|
-
|
-
|
-
|
EPS
2 |
-3.800
|
-47.20
|
-25.90
|
-1.700
|
-2.000
|
-2.000
|
-2.500
|
-0.8000
|
-
|
-0.5000
|
-0.0800
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/22
|
5/12/22
|
9/20/22
|
11/10/22
|
2/10/23
|
2/9/23
|
6/14/23
|
8/10/23
|
11/9/23
|
2/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
329
|
369
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
21.9
|
211
|
73.3
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-2.108
x
|
-1.797
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-606
|
-693
|
-264
|
-142
|
-128
|
-68.9
|
-14.8
|
31
|
ROE (net income / shareholders' equity)
|
-9.8%
|
-11.7%
|
-12.4%
|
-11.6%
|
-
|
-4.9%
|
-0.8%
|
4.3%
|
ROA (Net income/ Total Assets)
|
-7.87%
|
-9.21%
|
-9.65%
|
-8.46%
|
-
|
-2.7%
|
-0.4%
|
2.2%
|
Assets
1 |
3,695
|
35,943
|
7,205
|
20,315
|
-
|
2,293
|
1,938
|
254.1
|
Book Value Per Share
|
518.0
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-22.70
|
-34.60
|
-12.50
|
-5.110
|
-
|
-0.0600
|
0.2200
|
0.7800
|
Capex
1 |
414
|
355
|
53.1
|
32.2
|
12.1
|
13.1
|
11.9
|
9.99
|
Capex / Sales
|
167.1%
|
127.29%
|
21.62%
|
14.55%
|
6.93%
|
4.83%
|
3.72%
|
2.72%
|
Announcement Date
|
9/11/19
|
9/22/20
|
9/27/21
|
9/20/22
|
6/14/23
|
-
|
-
|
-
|
Last Close Price
9.19
CAD Average target price
9.681
CAD Spread / Average Target +5.35% Consensus |
1st Jan change
|
Capi.
|
---|
| +41.38% | 366M | | -15.13% | 4.51B | | -9.75% | 3.15B | | +2.14% | 3.1B | | -6.82% | 2.42B | | +47.87% | 1.97B | | +0.09% | 1.65B | | -7.89% | 1.68B | | -12.97% | 1.53B | | +33.40% | 1.38B |
Alternative Medicine
|